UroGen Pharma Ltd (URGN) support and resistance · rev $123.4M
UroGen Pharma Ltd (URGN) is a biotechnology company listed on NASDAQ.
This page maps UroGen Pharma Ltd (URGN) support and resistance from cached range and valuation — not a live tape and not a trade alert.
Latest reported URGN revenue for 2026-06-30 was $123.4M. Net income was -$37.9M. URGN currently screens at market cap $1.61B.
URGN currently screens at market cap $1.61B. Round numbers near that cap and multiple often act as psychological resistance; prior-period revenue is the fundamental floor traders argue about.
A new URGN 8-K or 10-Q can move the levels that matter more than a drawing on a chart.
Not investment advice. Use the URGN quote page for the session range and the stock page for the full model.
Not investment advice.